Rhythm Pharmaceuticals (RYTM) Getting Somewhat Positive Press Coverage, Accern Reports

Press coverage about Rhythm Pharmaceuticals (NASDAQ:RYTM) has been trending somewhat positive this week, Accern reports. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Rhythm Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.3252196765249 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:

How to Become a New Pot Stock Millionaire

Shares of RYTM stock traded down $0.73 during trading hours on Friday, reaching $19.46. 87,759 shares of the company’s stock were exchanged, compared to its average volume of 110,922. The company has a market cap of $550.87 and a PE ratio of -6.88. Rhythm Pharmaceuticals has a fifty-two week low of $16.80 and a fifty-two week high of $33.81.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings results on Monday, March 12th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.14. sell-side analysts forecast that Rhythm Pharmaceuticals will post -2.3 earnings per share for the current year.

A number of equities analysts have recently issued reports on RYTM shares. BidaskClub downgraded Rhythm Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 29th. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price target on shares of Rhythm Pharmaceuticals in a research report on Monday, February 26th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $31.25.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3338769/rhythm-pharmaceuticals-rytm-getting-somewhat-positive-press-coverage-accern-reports.html.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Insider Buying and Selling by Quarter for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

AngioDynamics, Inc.  Given Average Recommendation of “Buy” by Analysts
AngioDynamics, Inc. Given Average Recommendation of “Buy” by Analysts
Comparing Consolidated Edison  & WEC Energy Group
Comparing Consolidated Edison & WEC Energy Group
Analysts’ Price Target Changes for April, 24th
Analysts’ Price Target Changes for April, 24th
Contrasting Rayonier Advanced Materials  and Celanese
Contrasting Rayonier Advanced Materials and Celanese
Stifel  & The Competition Head-To-Head Analysis
Stifel & The Competition Head-To-Head Analysis
$15.84 Million in Sales Expected for BeiGene  This Quarter
$15.84 Million in Sales Expected for BeiGene This Quarter


© 2006-2018 Ticker Report. Google+.